DK1642132T3 - Glycokonjugater og deres anvendelse som potentielle vacciner mod infektion med Shigella flexneri - Google Patents

Glycokonjugater og deres anvendelse som potentielle vacciner mod infektion med Shigella flexneri

Info

Publication number
DK1642132T3
DK1642132T3 DK04744281.9T DK04744281T DK1642132T3 DK 1642132 T3 DK1642132 T3 DK 1642132T3 DK 04744281 T DK04744281 T DK 04744281T DK 1642132 T3 DK1642132 T3 DK 1642132T3
Authority
DK
Denmark
Prior art keywords
glycoconjugates
shigella flexneri
against infection
vaccines against
potential vaccines
Prior art date
Application number
DK04744281.9T
Other languages
English (en)
Inventor
Armelle Phalipon
Farida Nato
Laurence Mulard
Philippe Sansonetti
Cyrille Grandjean
Francoise Baleux
Frederic Belot
Original Assignee
Centre Nat Rech Scient
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002434685A external-priority patent/CA2434685A1/en
Application filed by Centre Nat Rech Scient, Pasteur Institut, Inst Nat Sante Rech Med filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK1642132T3 publication Critical patent/DK1642132T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
DK04744281.9T 2003-07-04 2004-07-02 Glycokonjugater og deres anvendelse som potentielle vacciner mod infektion med Shigella flexneri DK1642132T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002434685A CA2434685A1 (en) 2003-07-04 2003-07-04 Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
CA002434668A CA2434668A1 (en) 2003-07-04 2003-07-07 Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
PCT/IB2004/002657 WO2005003775A2 (en) 2003-07-04 2004-07-02 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri

Publications (1)

Publication Number Publication Date
DK1642132T3 true DK1642132T3 (da) 2011-10-17

Family

ID=33565750

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04744281.9T DK1642132T3 (da) 2003-07-04 2004-07-02 Glycokonjugater og deres anvendelse som potentielle vacciner mod infektion med Shigella flexneri
DK10011475.0T DK2369345T3 (da) 2003-07-04 2004-07-02 Glycokonjugater og deres anvendelse som potentielle vacciner mod infektion med Shigella flexneri

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10011475.0T DK2369345T3 (da) 2003-07-04 2004-07-02 Glycokonjugater og deres anvendelse som potentielle vacciner mod infektion med Shigella flexneri

Country Status (6)

Country Link
US (2) US8124380B2 (da)
EP (2) EP2369345B1 (da)
AT (1) ATE514087T1 (da)
CA (2) CA2434668A1 (da)
DK (2) DK1642132T3 (da)
WO (1) WO2005003775A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5069920B2 (ja) * 2007-02-08 2012-11-07 公益財団法人東京都医学総合研究所 マンノース６−リン酸−ポリエチレングリコール結合体
CA2591253A1 (en) 2007-06-05 2008-12-05 Institut Pasteur Specific oligosaccharides of shigella flexneri serotypes 3a and x, their synthesis, compositions comprising them and their uses thereof
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
EP2123668A1 (en) 2008-05-22 2009-11-25 Institut Pasteur Immunogenic polypeptides that mimic the surface polysaccharide O-antigen from serotype 2A shigella flexneri, method for obtaining the same, and their use in vaccine and diagnostic compositions
WO2010019890A2 (en) 2008-08-15 2010-02-18 The Government Of The Usa, As Represented By The Secretary Of The Dept. Of Health & Human Services Vaccine for shigella
EP2341941A4 (en) * 2008-09-09 2014-12-10 Univ Oklahoma HEPAROSANPOLYMERS AND METHOD FOR THE PRODUCTION THEREOF AND THEIR USE THEREOF FOR THE REINFORCEMENT OF THERAPEUTICS
JP5605541B2 (ja) * 2009-03-06 2014-10-15 国立大学法人埼玉大学 フコシルキトビオース誘導体の製造方法
EP2411039A4 (en) * 2009-03-23 2015-05-06 Brigham & Womens Hospital Glycoconjugate VACCINES
EP2386563A1 (en) * 2010-05-12 2011-11-16 Institut Pasteur Novel O-acetylated decasaccharides
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
EP2724730A1 (en) * 2012-10-29 2014-04-30 Institut Pasteur Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri
SG11201700325SA (en) 2014-08-08 2017-02-27 Glycovaxyn Ag Modified host cells and hybrid oligosaccharides for use in bioconjugate production
BR112017006447A2 (pt) * 2014-10-09 2017-12-12 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd processo de conjugação e conjugados sintéticos de oligossacarídeo-proteína obtidos dos mesmos
CN115003330A (zh) * 2019-09-23 2022-09-02 科纳克斯资本 作为疫苗和诊断工具的新糖缀合物
EP4106880A4 (en) * 2020-02-17 2024-07-03 Board of Regents, The University of Texas System HUMAN 4-1BB AGONIST ANTIBODIES AND METHODS OF USE THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5738855A (en) 1994-10-17 1998-04-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide
EP1000076A1 (en) * 1997-07-17 2000-05-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES HEXADECASACCHARIDE-PROTEIN CONJUGATE VACCINE FOR $i(SHIGELLA DYSENTERIAE) TYPE 1
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP1372707A1 (en) 2001-04-06 2004-01-02 Institut Pasteur Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of vibrio cholerae 0139 bound to tetanus toxoid
CN1646160A (zh) * 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
US20030235818A1 (en) * 2002-04-08 2003-12-25 Vsevolod Katritch Immunogenic peptides, and method of identifying same
JP2007525409A (ja) 2003-01-08 2007-09-06 アプライド モレキュラー エボリューション，インコーポレイテッド ＴＮＦ−α結合分子

Also Published As

Publication number Publication date
EP1642132A2 (en) 2006-04-05
US20080112951A1 (en) 2008-05-15
EP2369345A1 (en) 2011-09-28
WO2005003775A9 (en) 2008-11-06
CA2470262A1 (en) 2005-01-04
US20140161793A2 (en) 2014-06-12
CA2434668A1 (en) 2005-01-04
US20130243751A1 (en) 2013-09-19
EP1642132B1 (en) 2011-06-22
WO2005003775A3 (en) 2005-05-06
DK2369345T3 (da) 2015-01-12
CA2470262C (en) 2013-01-08
WO2005003775A2 (en) 2005-01-13
US9446109B2 (en) 2016-09-20
EP2369345B1 (en) 2014-10-01
US8124380B2 (en) 2012-02-28
ATE514087T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
DK1642132T3 (da) Glycokonjugater og deres anvendelse som potentielle vacciner mod infektion med Shigella flexneri
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
CY1109385T1 (el) Αναστολεις γυρασης και χρησεις αυτων
DE60144392D1 (de) Antivirale mittel
CY1113858T1 (el) Παραγωγα πυριδιν-3-υλιου ως ανοσορυθμιστικοι παραγοντες
NO20075069L (no) Vaksiner mot Clamydia infeksjon
IS2734B (is) Pýrasólafleiður og notkun þar á, ásamt lyfjasamsetningum
EA200702575A1 (ru) Иммуногенная композиция
CY1109202T1 (el) Συνθεσεις που περιεχουν αντιγονα απο τους οροτυπους b και c της neisseria meningitidis οπως και επιπλεον αντιγονα απο τον οροτυπο α
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
DK1427711T3 (da) Oxazolidinon og/eller isoxazolinderivater som antibakterielle midler
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
CY1111437T1 (el) Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης
NO20074895L (no) Isoksazolin derivat og ny fremgangsmate for fremstilling derav
CY1110745T1 (el) Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
ECSP055725A (es) Formulaciones nutricionales que contienen sustancias simbióticas
DK1915150T3 (da) Anvendelse af thienopyridinonderivater som AMPK-aktivatorer og farmaceutiske sammensætninger
MXPA05009352A (es) Metodos y composiciones para tratamiento y prevencion de staphylococcus y otras infecciones bacterianas.
CY1108625T1 (el) Φαρμακευτικες συνθεσεις για τη χορηγηση απο το στομα ηπαρινης ή παραγωγων της
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
CY1108808T1 (el) Ενωσεις μοτιλιδης
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
GEP20094834B (en) Macrolides, pharmaceutical compositions containing them and their use for treatment of bacterial infections
NO20044549L (no) Bisykliske 6-alkaliden-penemer som beta-laktamaseinhibitorer
NO20076405L (no) Anvendelse av 24-nor-UDCA